Selected article for: "lung cancer patient and lymphoma cell"

Author: Colombi, Davide; Bodini, Flavio Cesare; Morelli, Nicola; Silva, Mario; Milanese, Gianluca; Cavanna, Luigi; Michieletti, Emanuele
Title: COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients()
  • Cord-id: u7mbtwxi
  • Document date: 2020_9_10
  • ID: u7mbtwxi
    Snippet: We present three patients affected by pulmonary squamous cell carcinoma, metastatic esophageal cancer and advanced non-Hodgkin lymphoma, who incurred in coronavirus 2019 (COVID-19) infection during the early phase of epidemic wave in Italy. All patients presented with fever. Social contact with subject positive for COVID-19 was declared in only one of the three cases. In all cases, laboratory findings showed lymphopenia and elevated C-reactive protein (CRP). Chest x-ray and computed tomography s
    Document: We present three patients affected by pulmonary squamous cell carcinoma, metastatic esophageal cancer and advanced non-Hodgkin lymphoma, who incurred in coronavirus 2019 (COVID-19) infection during the early phase of epidemic wave in Italy. All patients presented with fever. Social contact with subject positive for COVID-19 was declared in only one of the three cases. In all cases, laboratory findings showed lymphopenia and elevated C-reactive protein (CRP). Chest x-ray and computed tomography showed bilateral ground-glass opacities, shadowing, interstitial abnormalities, and “crazy paving” pattern which evolved with superimposition of consolidations in one patient. All patients received antiviral therapy based on ritonavir and lopinavir, associated with hydroxychloroquine. Despite treatment, two patients with advanced cancers died after 39 and 17 days of hospitalization, while the patient with lung cancer was dismissed at home, in good conditions.

    Search related documents:
    Co phrase search for related documents
    • abnormality extent and acute ards respiratory distress syndrome: 1
    • acute ards respiratory distress syndrome and administration management: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and local bilateral: 1
    • acute ards respiratory distress syndrome and lombardy region: 1, 2
    • acute ards respiratory distress syndrome and low medium: 1, 2, 3
    • acute ards respiratory distress syndrome and low middle: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and lung toxicity: 1
    • acute ards respiratory distress syndrome and lung volume: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission day and lombardy region: 1
    • admission day and low medium: 1
    • admission day and low middle: 1, 2, 3
    • admission day and lung volume: 1, 2, 3
    • admission day and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • local bilateral and lymphocyte count: 1, 2
    • low medium and lung volume: 1
    • low medium and lymphocyte count: 1, 2
    • low middle and lymphocyte count: 1, 2